Xspray Pharma: HyNap-Dasa, a no-brainer for BMS?

We have delved deeper in historical patent litigations with focus on amorphous vs crystalline candidates, and highlight a recent case which ended in a settlement between the generic and original company. These findings reinforce our belief that a deal could be reached shortly after the study data. Thus, we revalue our estimates, which leads to higher valuations.

Read more and download the Research Update

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/